Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program

Απλή σελίδα τεκμηρίου
dc.contributor.authorRazis, E.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorDimopoulos, M.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorLambropoulos, S.en
dc.contributor.authorRigatos, S.en
dc.contributor.authorKopterides, P.en
dc.contributor.authorEfstathiou, H.en
dc.contributor.authorTzamakou, E.en
dc.contributor.authorBakoyannis, C.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorVarthalitis, G.en
dc.contributor.authorPapadopoulos, S.en
dc.contributor.authorKosmidis, P.en
dc.date.accessioned2015-11-24T19:05:47Z
dc.date.available2015-11-24T19:05:47Z
dc.identifier.issn0959-4973-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20243
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Agents/adverse effects/*therapeutic useen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectQuinazolines/adverse effects/*therapeutic useen
dc.subjectReceptor, Epidermal Growth Factor/antagonists & inhibitorsen
dc.subjectRetrospective Studiesen
dc.subjectSurvival Analysisen
dc.subjectTreatment Outcomeen
dc.titleTreatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use programen
heal.abstractThis is a retrospective analysis of 150 patients with advanced non-small cell lung cancer who had failed prior treatment or were unfit for chemotherapy and were treated with oral gefitinib ('Iressa', ZD1839; AstraZeneca) 250 mg/day. Thirty-two patients who received gefitinib for 3 weeks or less were not included in the analysis. For the remaining 118 evaluable patients, the mean age was 63.1 years; most patients had received prior chemotherapy (97.5%), Eastern Cooperative Oncology Group performance status scores 0-2 (97.4%) and stage IV disease (64.4%). The majority were symptomatic (84.6%). Disease control was observed in 30 patients (25.4%), of whom five had a partial response and 25 had stable disease; 18 (15.3%) were not evaluable. Median duration of treatment was 29.9 weeks in responding patients and 11.5 in patients with progressive disease (p<0.0001). Median overall survival was 7.3 months (15.2 months for disease control) and median progression-free survival was 3.2 months. Gefitinib was well tolerated, with grade 3/4 skin rash and diarrhea seen in 2.5 and 4.2% of patients, respectively. Clinical benefit was evaluated using questionnaires before and following treatment with gefitinib. In 82 patients with completed questionnaires, evaluation revealed symptom improvement in 40.1% and improvement in general feeling in 31.4%. Epidermal growth factor receptor (EGFR) analysis found that efficacy did not correlate with tumor EGFR overexpression. Therefore, in this retrospective analysis, gefitinib treatment provided disease control in 25% of patients who derived significant palliative benefit.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15655417-
heal.journalNameAnticancer Drugsen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ